Patient Characteristics and Chemotherapy Regimens
| Characteristic | Total (n = 92) |
|---|---|
| Median age, y (range) | 54 (19–78) |
| Sex: men/women | 60/32 |
| Ann Arbor stage, no. (%) | |
| I−II | 11 (12) |
| III−IV | 81 (88) |
| Standard IPI score, no. (%) | |
| Low risk (L) | 20 (22) |
| Low-intermediate (LI) | 18 (19) |
| High-intermediate (HI) | 30 (33) |
| High (H) | 24 (26) |
| Chemotherapy regimen, no. (%) | |
| CHOP | 3 (3) |
| R-CHOP | 27 (29) |
| ACVBP/ACE | 42 (46) |
| R-ACVBP | 20 (22) |
IPI = International Prognostic Index; CHOP = cyclophosphamide, hydroxydaunomycin, oncovin (vincristine), prednisone; R = rituximab; ACVBP = adriamycin (doxorubicin), cyclophosphamide, vindesine, bleomycin, prednisone; ACE = adriamycin, cyclophosphamide, etoposide.